Interwest Venture Management Co. Boosts Stake in Glaukos Corp (NYSE:GKOS)

Interwest Venture Management Co. increased its stake in shares of Glaukos Corp (NYSE:GKOS) by 137.8% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 7,995 shares of the medical instruments supplier’s stock after purchasing an additional 4,633 shares during the period. Glaukos makes up approximately 0.2% of Interwest Venture Management Co.’s investment portfolio, making the stock its 11th largest position. Interwest Venture Management Co.’s holdings in Glaukos were worth $602,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Meeder Asset Management Inc. acquired a new stake in Glaukos during the 1st quarter worth approximately $48,000. Marshall Wace North America L.P. acquired a new stake in shares of Glaukos in the 1st quarter valued at $55,000. NEXT Financial Group Inc raised its holdings in shares of Glaukos by 73.7% in the 2nd quarter. NEXT Financial Group Inc now owns 1,129 shares of the medical instruments supplier’s stock valued at $85,000 after purchasing an additional 479 shares in the last quarter. First Quadrant L P CA acquired a new stake in shares of Glaukos in the 2nd quarter valued at $86,000. Finally, Oppenheimer Asset Management Inc. raised its holdings in shares of Glaukos by 251.7% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 1,938 shares of the medical instruments supplier’s stock valued at $152,000 after purchasing an additional 1,387 shares in the last quarter. 95.94% of the stock is owned by hedge funds and other institutional investors.

In other Glaukos news, CFO Joseph E. Gilliam sold 10,346 shares of the firm’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $75.41, for a total transaction of $780,191.86. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 27,846 shares of company stock worth $2,032,121 over the last three months. 8.70% of the stock is currently owned by insiders.

Shares of Glaukos stock opened at $76.32 on Wednesday. Glaukos Corp has a 1 year low of $38.04 and a 1 year high of $84.65. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.72 and a quick ratio of 6.23. The stock has a market cap of $2.95 billion, a P/E ratio of -206.27 and a beta of 1.61. The stock’s fifty day simple moving average is $76.85.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.08. Glaukos had a negative net margin of 5.93% and a negative return on equity of 6.90%. The company had revenue of $54.03 million for the quarter, compared to the consensus estimate of $50.13 million. As a group, sell-side analysts anticipate that Glaukos Corp will post -0.3 earnings per share for the current year.

GKOS has been the topic of a number of analyst reports. BMO Capital Markets raised their price objective on shares of Glaukos from $66.00 to $71.00 and gave the company a “market perform” rating in a report on Thursday, May 9th. Zacks Investment Research upgraded shares of Glaukos from a “hold” rating to a “strong-buy” rating and set a $82.00 price target on the stock in a research note on Tuesday, April 30th. Finally, BTIG Research reiterated a “hold” rating on shares of Glaukos in a research note on Wednesday, May 22nd. Three research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. Glaukos has a consensus rating of “Buy” and a consensus price target of $72.56.

Glaukos Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.

Featured Story: What can cause a stock to outperform?

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.